Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ociperlimab + Tislelizumab vs Placebo + Tislelizumab in Second-line Advanced ESCC
CTR20210243Phase 2Completed
- Sponsor
- BeiGene
- Start
- Feb 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, IgG Antibodies → Naked Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of ociperlimab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by BeiGene. Started Feb 2021; status: completed.
02
Drugs
ociperlimab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on CTR20210243.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210243.